SIRPA and neoplasm: BI 765063 prevents ligand binding between SIRPα and CD47 by binding to SIRPα, thereby blocking cellular signaling that would lead to a decrease in anti-tumor substances (e.g., macrophages and DCs) in myeloid cells.